Hørsholm, Denmark, January 09, 2024
Today, we are happy to announce that Inphena A/S has acquired all shares in AFYX Therapeutics A/S. The transaction came in place after the majority shareholders Sofinnova, Novo Holdings and the Lundbeck Foundation decided that the transaction was in the best interest of all parties and that it would secure the continued development of the Rivelin Patch technology.
Inphena A/S is a niche biopharmaceutical company with focus on reformulation and repurposing of pharmaceuticals.
CLAUS J. MØLLER-SAN PEDRO
CEO & Founder
WE IMPROVE PEOPLE’S LIVES BY TRANSFORMING TOMORROW’S TREATMENTS
AFYX Therapeutics A/S – Our company is a niche biopharmaceutical company with focus on reformulation and repurposing of pharmaceuticals.
Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and has secured successful IPOs of 3 other companies in the BioPharma Industry (OXiGENE, Inc., Genmab A/S and Y-mAbs Therapeutics, Inc)
Our focus is:
• OBSTETRICS
• NICHE ONCOLOGY
• PAIN AND ADDICTION
Contact: inquiry@afyxtx.com | +45 7174 7174